

# A double-blind, placebo controlled, randomised study to assess the value of free radical scavengers in reducing inflammation induced by cryotherapy

<b>Submission date</b> 12/09/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 16/03/2009	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr F Humphreys

### Contact details

Department of Dermatology  
South Warwickshire General Hospitals NHS Trust  
Warwick Hospital  
Lakin Road  
Warwick  
United Kingdom  
CV34 5BW  
+44 (0)1926 495 321

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

N0593115224

# Study information

## Scientific Title

## Study objectives

The aims of the study are to investigate and quantify the response of:

1. Oedema and blister formation
2. Erythema
3. Pain induced by cryotherapy in patients receiving a combination of a high dose of systemic vitamins C and E prior to treatment in comparison to placebo group.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Double-blind, placebo controlled, randomised study

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Skin and Connective Tissue Diseases: Hand warts

## Interventions

Double-blind, parallel group, randomised study of the effect of a high dose combined systemic vitamin C and E on inflammation-induced cryotherapy.

1. Enrolment - It is proposed to enrol 100 patients with hand warts. Each patient will be assigned a unique number. Subjects will be patients referred to the Dermatology Department for the treatment of hand warts. Subjects will be required to provide written informed consent.
2. Randomisation Treatment will be allocated by randomising patients into balanced blocks of four. The pharmaceutical company providing the drugs will be responsible for the process of randomisation.

3. Study drug administration - Patients with hyperkeratotic hand warts (size 4-8 mm) will receive either a combined preparation of vitamin C (2000 mg) and vitamin E (800 iu) daily or placebo for 7 days prior to cryotherapy to a hand wart.

4. Treatment with Cryotherapy - The wart will be treated with a single application of cryotherapy from CRY-AC spray to obtain a 1-mm halo around the wart and just sufficient to maintain this for further 10 s. The CRY-AC spray will be half full with liquid nitrogen and the nozzle will be kept approximately 1cm away from the treated lesion. Different size cardboard templates will be treated with liquid nitrogen. Patients will be seen and assessed 24 h after cryotherapy.

**Intervention Type**

Supplement

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Vitamin C, vitamin E

**Primary outcome measure**

Change in wart volume assessed 24 h after cryotherapy for the grade of oedema.

**Secondary outcome measures**

Not provided at time of registration

**Overall study start date**

01/01/2002

**Completion date**

31/12/2004

**Eligibility****Key inclusion criteria**

100 randomised (1:1) patients aged 18 years and over referred to the dermatology clinic for cryotherapy of hand warts that have failed to respond to topical salicylic acid preparations will be asked after appropriate counselling to participate in the trial.

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2002

**Date of final enrolment**

31/12/2004

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

Department of Dermatology

Warwick

United Kingdom

CV34 5BW

## Sponsor information

**Organisation**

Department of Health (UK)

**Sponsor details**

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

**Sponsor type**

Government

**Website**

<http://www.doh.gov.uk>

## Funder(s)

**Funder type**  
Government

**Funder Name**  
South Warwickshire General Hospitals NHS Trust (UK)

## Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/01/2005		Yes	No